Does the media favor ACAD or RIGL?

In the previous week, ACADIA Pharmaceuticals had 17 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 21 mentions for ACADIA Pharmaceuticals and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.42 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CDNA or RIGL?

In the previous week, CareDx and CareDx both had 4 articles in the media. CareDx's average media sentiment score of 0.52 beat Rigel Pharmaceuticals' score of 0.42 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMLX or RIGL?

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 4 mentions for Rigel Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.88 beat Rigel Pharmaceuticals' score of 0.42 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RIGL or ELVN?

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 4 articles in the media. Enliven Therapeutics' average media sentiment score of 1.18 beat Rigel Pharmaceuticals' score of 0.42 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNLI or RIGL?

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Rigel Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.67 beat Rigel Pharmaceuticals' score of 0.42 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rigel Pharmaceuticals (RIGL) Competitors

$47.15 +0.18 (+0.38%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$47.15 +0.00 (+0.01%)

As of 10/2/2026 07:38 PM Eastern

Compare

RIGL vs. ACAD, CDNA, AMLX, ELVN, and DNLI

Should you buy Rigel Pharmaceuticals stock or one of its competitors? Rigel Pharmaceuticals's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), CareDx (CDNA), Amylyx Pharmaceuticals (AMLX), Enliven Therapeutics (ELVN), and Denali Therapeutics (DNLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

ACADIA Pharmaceuticals currently has a consensus price target of $32.76, indicating a potential upside of 64.23%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 25.13%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

ACADIA Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 17 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 21 mentions for ACADIA Pharmaceuticals and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.42 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rigel Pharmaceuticals has a net margin of 116.30% compared to ACADIA Pharmaceuticals' net margin of 33.42%. Rigel Pharmaceuticals' return on equity of 22.95% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

ACADIA Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.21	$391M	$2.22	8.99
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Rigel Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to CareDx?

CareDx (NASDAQ:CDNA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Rigel Pharmaceuticals has a net margin of 116.30% compared to CareDx's net margin of 24.23%. Rigel Pharmaceuticals' return on equity of 22.95% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CareDx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

CareDx currently has a consensus target price of $54.00, suggesting a potential downside of 19.58%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 25.13%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has lower revenue, but higher earnings than CareDx. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	9.15	-$21.35M	$2.07	32.44
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

In the previous week, CareDx and CareDx both had 4 articles in the media. CareDx's average media sentiment score of 0.52 beat Rigel Pharmaceuticals' score of 0.42 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rigel Pharmaceuticals beats CareDx on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Amylyx Pharmaceuticals presently has a consensus price target of $38.86, indicating a potential upside of 39.82%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 25.13%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Amylyx Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	35.44	-$144.74M	-$1.43	N/A
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

Amylyx Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 4 mentions for Rigel Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.88 beat Rigel Pharmaceuticals' score of 0.42 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amylyx Pharmaceuticals beats Rigel Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Enliven Therapeutics?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Rigel Pharmaceuticals has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Rigel Pharmaceuticals has a net margin of 116.30% compared to Enliven Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Enliven Therapeutics	N/A	-18.55%	-18.09%

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 25.13%. Enliven Therapeutics has a consensus target price of $74.44, suggesting a potential upside of 58.49%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Rigel Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 4 articles in the media. Enliven Therapeutics' average media sentiment score of 1.18 beat Rigel Pharmaceuticals' score of 0.42 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats Enliven Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Denali Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Rigel Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.67 beat Rigel Pharmaceuticals' score of 0.42 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics currently has a consensus price target of $35.85, suggesting a potential upside of 79.23%. Rigel Pharmaceuticals has a consensus price target of $59.00, suggesting a potential upside of 25.13%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Denali Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.67	-$512.54M	-$2.84	N/A
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

Rigel Pharmaceuticals has a net margin of 116.30% compared to Denali Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Summary

Rigel Pharmaceuticals beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$872.37M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	2.89	13.00	275.67	26.04
Price / Sales	2.96	1,289.24	656.66	105.14
Price / Cash	6.99	123.39	78.87	52.62
Price / Book	2.19	16.57	10.93	6.31
Net Income	$367.02M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-2.14%	-2.97%	-2.00%	-1.66%
1 Month Performance	-3.12%	-10.82%	-6.19%	-4.68%
1 Year Performance	65.21%	19.00%	8.03%	1.57%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	3.8421 of 5 stars	$47.15 +0.4%	$59.00 +25.1%	+65.2%	$872.37M	$294.28M	2.89	174	News Coverage
ACAD ACADIA Pharmaceuticals	4.3633 of 5 stars	$20.53 -0.7%	$32.76 +59.6%	-8.5%	$3.56B	$1.07B	9.25	798	Analyst Downgrade Analyst Revision
CDNA CareDx	2.3182 of 5 stars	$64.60 +1.4%	$54.00 -16.4%	+342.1%	$3.29B	$379.80M	31.21	765
AMLX Amylyx Pharmaceuticals	3.1975 of 5 stars	$29.85 +1.2%	$38.86 +30.2%	+107.1%	$3.29B	$87.37M	N/A	136	News Coverage
ELVN Enliven Therapeutics	3.0729 of 5 stars	$46.01 +2.8%	$75.00 +63.0%	+139.5%	$3.28B	N/A	N/A	67	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. ACAD, CDNA, AMLX, ELVN, and DNLI

How does Rigel Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Rigel Pharmaceuticals compare to CareDx?

Summary

How does Rigel Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does Rigel Pharmaceuticals compare to Enliven Therapeutics?

Summary

How does Rigel Pharmaceuticals compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. ACAD, CDNA, AMLX, ELVN, and DNLI

How does Rigel Pharmaceuticals compare to ACADIA Pharmaceuticals?

Do analysts recommend ACAD or RIGL?

Which has more risk & volatility, ACAD or RIGL?

Does the media favor ACAD or RIGL?

Is ACAD or RIGL more profitable?

Which has stronger earnings & valuation, ACAD or RIGL?

Do insiders and institutionals believe in ACAD or RIGL?

Summary

How does Rigel Pharmaceuticals compare to CareDx?

Is CDNA or RIGL more profitable?

Do insiders and institutionals hold more shares of CDNA or RIGL?

Which has more volatility & risk, CDNA or RIGL?

Do analysts recommend CDNA or RIGL?

Which has better valuation and earnings, CDNA or RIGL?

Does the media favor CDNA or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Amylyx Pharmaceuticals?

Is AMLX or RIGL more profitable?

Do analysts rate AMLX or RIGL?

Do insiders & institutionals have more ownership in AMLX or RIGL?

Which has preferable valuation & earnings, AMLX or RIGL?

Which has more volatility & risk, AMLX or RIGL?

Does the media refer more to AMLX or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Enliven Therapeutics?

Which has higher earnings and valuation, RIGL or ELVN?

Is RIGL or ELVN more profitable?

Do insiders & institutionals hold more shares of RIGL or ELVN?

Do analysts rate RIGL or ELVN?

Which has more risk & volatility, RIGL or ELVN?

Does the media prefer RIGL or ELVN?

Summary

How does Rigel Pharmaceuticals compare to Denali Therapeutics?

Do insiders and institutionals have more ownership in DNLI or RIGL?

Which has more risk & volatility, DNLI or RIGL?

Does the media favor DNLI or RIGL?

Do analysts prefer DNLI or RIGL?

Which has better earnings & valuation, DNLI or RIGL?

Is DNLI or RIGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools